Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
January 2023
-
Featured NewsNovartis provides update on Phase III STAND trial assessing crizanlizumab
-
Media ReleaseSandoz announces agreement to acquire leading antifungal agent Mycamine® from Astellas, reinforcing hospital offering and leading Anti-Infectives portfolioSandoz plans to acquire worldwide product rights for Mycamine®(micafungin sodium) from AstellasAcquiring leading global echinocandin, one of three major antifungal classes, will significantly…
-
Featured NewsWorld Economic Forum 2023 -
Featured NewsNovartis shares strategy insights and highlights key pipeline catalysts at JP Morgan Healthcare Conference 2023
-
Featured NewsZolgensma Global Managed Access Program in 2023
December 2022
-
Story Access to Healthcare
Compassionate use: Providing access to much needed treatments -
Media ReleaseNovartis presents pivotal Phase III APPLY-PNH data at ASH demonstrating investigational oral monotherapy iptacopan superiority over anti-C5Trial met both primary and most secondary endpoints, showing iptacopan provided transfusion-free hemoglobin-level increases in vast majority of adult paroxysmal nocturnal hemoglobinuria (PNH)…
-
Media ReleaseNovartis receives European Commission approval for Pluvicto® as the first targeted radioligand therapy for treatment of progressive PSMA–positive metastatic castration-resistant prostate cancerEC approval based on results from pivotal Phase III VISION trial, in which Pluvicto® plus best standard of care (BSoC) significantly improved overall survival and radiographic progression-free…
-
Media ReleaseNovartis investigational iptacopan provides clinically meaningful increases in hemoglobin levels in complement-inhibitor-naïve patients with PNHPhase III APPOINT-PNH study of investigational oral monotherapy iptacopan met its primary endpoint; second positive Phase III topline readout for iptacopan in paroxysmal nocturnal hemoglobinuria (PNH…
-
Media ReleaseNovartis Kisqali® prolonged PFS benefit for pre- and perimenopausal patients with aggressive HR+/HER2− metastatic breast cancer compared to chemotherapyRIGHT Choice Phase II trial is the first randomized study in patients with aggressive HR+/HER2− metastatic breast cancer (MBC), including visceral crisis, comparing a CDK4/6 inhibitor (CDK4/6i) plus…
-
Media ReleaseNovartis Pluvicto™ shows statistically significant and clinically meaningful radiographic progression-free survival benefit in patients with PSMA–positive metastatic castration-resistant prostate cancerAd hoc announcement pursuant to Art. 53 LR Phase III PSMAfore trial with PluvictoTM met the primary endpoint of radiographic progression-free survival (rPFS) in PSMA–positive mCRPC who have been…
